zasocitinib

Small molecule

Also known as TAK-279, NDI-034858

Filedunder review

Evidence outlook · regulatory review

Psoriasis: application under FDA review

Zasocitinib NDA under Priority Review (2026-09-14). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.

NCT06973291: This Phase 3 trial was randomized and double-blind, comparing zasocitinib directly against an active comparator (deucravacitinib) in 606 adults with plaque psoriasis. Its primary endpoint, complete skin clearance (PASI-100) at Week 16, was met: more than 35% of zasocitinib-treated patients achieved complete clearance, over 2.5 times the rate seen with deucravacitinib.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Also in development:Psoriatic Arthritis · Phase 3Vitiligo · Phase 2Hidradenitis Suppurativa · Phase 2

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (11)
Psoriasis
NCT07250802 · Takeda
2025-12-04 – 2034-07-03 · Plaque Psoriasis
What this study did
NCT06550076 · Takeda
2024-09-04 – 2029-08-05 · Plaque Psoriasis
What this study did
NCT07752108 · Takeda
2026-11-16 – 2029-02-15 · Palmoplantar Psoriasis
What this study did
Psoriatic Arthritis
NCT07871721 · Takeda
2027-01-11 – 2030-12-30 · Psoriatic Arthritis
What this study did
NCT07286058 · Takeda
2026-03-11 – 2029-12-18 · Psoriatic Arthritis
What this study did
Phase 2 (8)
Hidradenitis Suppurativa
NCT07244263 · Takeda
2026-01-26 – 2028-02-22 · Hidradenitis Suppurativa
What this study did
Psoriasis
NCT04999839 · Takeda
2021-08-11 – 2022-09-12 · Moderate to Severe Plaque Psoriasis
What this study did
Psoriatic Arthritis
NCT05153148 · Takeda
2022-01-06 – 2023-06-02 · Psoriatic Arthritis
What this study did
Vitiligo
NCT07108283 · Takeda
2025-11-03 – 2027-11-09 · Nonsegmental Vitiligo
What this study did
Other / comorbidity
NCT06764615 · Takeda
2025-05-28 – 2029-12-30 · Crohn's Disease, Ulcerative Colitis
What this study did
NCT07403968 · Takeda
2026-08-13 – 2028-03-30 · Crohn's Disease
What this study did
NCT06254950 · Takeda
2024-03-29 – 2027-08-04 · Ulcerative Colitis
What this study did
Phase 1 (7)
Other / comorbidity
NCT06793943 · Takeda
2025-01-23 – 2025-03-30 · Healthy Volunteers
What this study did
NCT06111547 · Takeda
2024-06-24 – 2024-08-04 · Healthy Volunteers
What this study did
NCT06258265 · Takeda
2024-04-29 – 2024-07-09 · Healthy Volunteers
What this study did
NCT05992155 · Takeda
2023-09-27 – 2024-05-28 · Renal Impairment, Healthy Volunteers
What this study did
NCT06290050 · Takeda
2024-03-29 – 2024-05-16 · Healthy Volunteers
What this study did
NCT05976321 · Takeda
2023-09-22 – 2024-04-15 · Hepatic Impairment, Healthy Volunteers
What this study did
NCT05995249 · Takeda
2023-08-11 – 2023-12-31 · Healthy Volunteers
What this study did

Competitive landscape

This mechanism is crowded: 13 other tracked programmes target it, 1 of them ahead of this one.

This drug's own stage for Hidradenitis Suppurativa: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Zasocitinib: this drugPhase 2Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Bimekizumab (Bimzelx)ApprovedMonoclonal antibodyIL-17A/FPartial signal
NCT04242498: HiSCR50 at week 16: bimekizumab dosing regimen 1 53.8% (n=144) and regimen 2 52.0% (n=291) vs placebo 32.2% (n=74); odds ratios 2.42 (95% CI 1.22 to 4.80), p=0.004, and 2.29 (95% CI 1.22 to 4.29), p=0.003 (CT.gov posted results).
NCT04242446: Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16 (Week 16): Placebo 28.7 percentage of participants (95% CI 18.1 to 39.3) | BKZ Dosing Regimen 1 45.3 percentage of participants (95% CI 36.8 to 53.8) | BKZ Dosing Regimen 2 47.8 percentage of participants (95% CI 41.8 to 53.7)
Secukinumab (Cosentyx)ApprovedMonoclonal antibodyIL-17Partial signal
NCT03713632: Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50) (16 weeks): AIN457 Q2W 42.3 Percentage of Participants | AIN457 Q4W 46.1 Percentage of Participants | Placebo 31.2 Percentage of Participants
NCT03713619: Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50) (16 weeks): Secukinumab 1 - Q2W 45 Percentage of participants | Secukinumab 2 - Q4W 41.8 Percentage of participants | Placebo 33.7 Percentage of participants
LutikizumabPhase 3Multispecific antibodyIL-1α/IL-1β (dual)not yet gradedNo reviewed efficacy summary in this indication
RemibrutinibPhase 3Small moleculeBruton's tyrosine kinase (BTK)not yet gradedNo reviewed efficacy summary in this indication
Ruxolitinib (Opzelura)Phase 3Small moleculeJAK1/2not yet gradedNo reviewed efficacy summary in this indication
SonelokimabPhase 3Antibody-derived scaffoldIL-17A/Fnot yet gradedNo reviewed efficacy summary in this indication
Upadacitinib (Rinvoq)Phase 3Small moleculeJAK, JAK1not yet gradedNo reviewed efficacy summary in this indication
BFB759Phase 2/3Monoclonal antibodyIL-1RAPnot yet gradedNo reviewed efficacy summary in this indication
Spesolimab (Spevigo)Phase 2/3Monoclonal antibodyIL-36 receptornot yet gradedNo reviewed efficacy summary in this indication
AbdakibartPhase 2Monoclonal antibodyIL-1 betanot yet gradedNo reviewed efficacy summary in this indication
DuvakitugPhase 2Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
EltrekibartPhase 2Monoclonal antibodyCXCR1/2not yet gradedNo reviewed efficacy summary in this indication
OlatorepatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
ORKA-002Phase 2Monoclonal antibodyIL-17A/Fnot yet gradedNo reviewed efficacy summary in this indication
SAR442970Phase 2——not yet gradedNo reviewed efficacy summary in this indication
SAR445399Phase 2Monoclonal antibodyIL-1R3 (IL1RAP)not yet gradedNo reviewed efficacy summary in this indication
SPY072Phase 2Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
TulisokibartPhase 2Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
A-005
Phase 1(overall)
Small moleculeTYK2
not yet graded(overall)
No reviewed efficacy summary in this indication
ABBV-1451
Phase 1(overall)
UndisclosedIL-1α/IL-1β (dual)not yet gradedNo reviewed efficacy summary in this indication
SAR447971
Phase 1(overall)
Small moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication
TipasertidegDiscontinuedSmall moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication

Compare side by side

5 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.

Upcoming events

(12 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow zasocitinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (6)
February 2027 (2)
Phase 2Hidradenitis SuppurativaActive not recruiting
Est. primary completion 2027-02-05 · NCT07244263 · CT.gov ↗
What to watch
Phase 2Crohn's DiseaseRecruiting
Est. primary completion 2027-02-17 · NCT06233461 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2VitiligoActive not recruiting
Est. primary completion 2027-03-26 · NCT07108283 · CT.gov ↗
What to watch
May 2027 (3)
Phase 3Psoriatic ArthritisActive not recruiting
Est. primary completion 2027-05-18 · NCT06671496 · CT.gov ↗
What to watch
Phase 3Psoriatic ArthritisActive not recruiting
Est. primary completion 2027-05-18 · NCT06671483 · CT.gov ↗
What to watch
Phase 3PsoriasisNot yet recruiting
Est. primary completion 2027-05-30 · NCT07752108 · CT.gov ↗
What to watch
2028 (1)
March 2028 (1)
Phase 2Crohn's DiseaseRecruiting
Est. primary completion 2028-03-30 · NCT07403968 · CT.gov ↗
What to watch
2029 (3)
August 2029 (1)
Phase 3PsoriasisActive not recruiting
Est. primary completion 2029-08-05 · NCT06550076 · CT.gov ↗
What to watch
December 2029 (2)
Phase 3Psoriatic ArthritisRecruiting
Est. primary completion 2029-12-18 · NCT07286058 · CT.gov ↗
What to watch
Phase 2Crohn's Disease, Ulcerative ColitisRecruiting
Est. primary completion 2029-12-30 · NCT06764615 · CT.gov ↗
What to watch
2030 (1)
April 2030 (1)
Phase 3Psoriatic ArthritisNot yet recruiting
Est. primary completion 2030-04-18 · NCT07871721 · CT.gov ↗
What to watch
2034 (1)
July 2034 (1)
Phase 3PsoriasisRecruiting
Est. primary completion 2034-07-03 · NCT07250802 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

14 September 2026Filing acceptedFDA accepts zasocitinib NDA
US, FDA · Takeda · Source ↗
14 September 2026Priority reviewZasocitinib NDA under Priority Review
US, FDA · Takeda · Source ↗
14 September 2026Filing acceptedEMA accepts zasocitinib MAA
EU, EMA · Takeda · Source ↗